Insta
First Batch Of DRDO-Developed Anti-COVID Drug '2-DG' Launched; Reduces Recovery Time, Oxygen Demand In Patients
The drug was jointly launched by Defence Minister and Health Minister on Monday (Pic Via PIB Website)
The first batch of the drug developed by the Defence Research and Development Organisation (DRDO) to treat moderate to severe Covid-19 patients was launched on Monday (17 May).
Minister of Defence Rajnath Singh and Minister of Health and Family Welfare, Dr Harsh Vardhan jointly launched the new COVID drug 2-DG at DRDO Bhawan.
The anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, along with Dr Reddy’s Laboratories (DRL), Hyderabad, the Defence Ministry said in a statement.
It will be administered to patients as an adjunct therapy or an alternative treatment to assist the primary treatment.
A DRDO statement had earlier said that the clinical trial showed that the drug helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence. The patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on various endpoints in the efficacy trends.
